Filing Details

Accession Number:
0001192482-19-000430
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-11-13 21:03:35
Reporting Period:
2019-11-08
Accepted Time:
2019-11-13 21:03:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1561921 Tela Bio Inc. TELA () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1497725 Quaker Bioventures Ii Lp 150 Monument Road, Suite 207
Bala Cynwyd PA 19004
No No Yes No
1583083 Quaker Bioventures Capital Ii, L.p. 150 Monument Road, Suite 207
Bala Cynwyd PA 19004
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-11-08 153,846 $13.00 888,664 No 4 P Direct
Common Stock Acquisiton 2019-11-13 345,489 $0.00 1,234,153 No 4 C Direct
Common Stock Acquisiton 2019-11-13 516,947 $0.00 1,751,100 No 4 C Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 C Direct
No 4 C Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2019-11-13 8,530,145 $0.00 345,489 $0.00
Common Stock Series B Preferred Stock Disposition 2019-11-13 12,763,434 $0.00 516,947 $0.00
Series B Preferred Stock Warrant (right to buy) Disposition 2019-11-13 446,813 $0.00 446,813 $1.16
Common Stock Warrant (right to buy) Disposition 2019-11-13 446,813 $0.00 18,096 $28.65
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
0 2017-01-18 2027-01-18 No 4 C Direct
446,813 2019-11-13 2027-01-18 No 4 C Direct
Footnotes
  1. Reflects 705,530 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
  2. Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
  3. Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
  4. Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.
  5. Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.